Alumis Shares Jump After Positive Psoriasis Data, Insider Buying, and Partnership Focus
Alumis shares rose sharply in pre-market trading following management presentations at two investor conferences that highlighted long-term psoriasis data for envudeucitinib, discussed partnership possibilities, and were reinforced by significant insider purchases by a company director. The company also reiterated a fourth-quarter 2026 New Drug Appl…